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Abstract
Viral load is an important tool for assessing antiretroviral treatment efficacy. However, the most 
common viral load endpoint, virologic failure, may be flawed. We illustrate an alternative 
endpoint that estimates the average time patients spent suppressed prior to rebound in the AIDS 
Clinical Trials Group A5095 trial. Patients averaged 644 days suppressed in the 3-drug arm and 
686 days suppressed in the 4-drug arm, for a difference of 42 days in favor of the 4-drug regimen 
(95% CI: −11, 96). These results agree with results using virologic failure as the endpoint but 
better emphasize the separate suppression and rebound processes.
Introduction
Plasma HIV-1 RNA (henceforth, viral load) is an important biomarker to monitor infection 
and to assess the prognosis of patients with HIV. Clinicians use measurements of viral load 
together with CD4 cell count, symptoms, and AIDS-defining illnesses to inform treatment 
decisions and assess the efficacy of a given antiretroviral treatment (ART) regimen 1.
Viral load is also an important measure for researchers wishing to describe effects of a 
treatment over time or to compare effects of treatment regimens 2. Perhaps the most 
commonly used endpoint to compare the efficacy of treatment plans is the time to “virologic 
failure” 3–7. The time to virologic failure for patients whose viral load is not suppressed by a 
predetermined time during the study period is often set to that predetermined time 5,6 or time 
zero 8. In addition, studies using virologic failure as an endpoint often ignore viremia prior 
to suppression by measuring the time to virologic failure as the time from study onset to 
viral rebound 7.
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Gouskova et al 9 formalized an alternative endpoint based on multistate methods 10 that uses 
information on time to both viral load suppression and rebound to estimate the probability of 
being suppressed as a function of time from study onset. Here, we provide an illustrative 
example in which we estimate this measure to compare the efficacy of two treatment 
regimens in a randomized trial.
Methods
We compare this alternative endpoint between treatment arms in publicly-available de-
identified data from the AIDS Clinical Trials Group A5095 trial 6 conducted between March 
2001 and March 2005. Briefly, 1125 therapy-naïve patients infected with HIV-1 were 
randomized to one of 3 arms: a triple-nucleoside regimen (zidovudine, lamivudine, and 
abacavir), a 3-drug standard of care regimen with efavirenz (zidovudine, lamivudine, and 
efavirenz), or a 4-drug regimen with efavirenz (zidovudine, lamivudine, abacavir, and 
efavirenz). We limit the analysis to patients randomized to the 3- and 4-drug efavirenz- 
containing regimens (as did Gulick et al 6) because the triple-nucleoside group was 
discontinued. Data for 761 of the 765 patients in the 3- and 4-drug arms were available in 
the public-use dataset. Treatment was initiated at randomization. Study visits were 
conducted at weeks 2, 4, 8, 12, 16, 20, 24, and then every 8 weeks, and viral load was 
measured at each study visit. Here we perform an intent-to-treat analysis in which we 
estimate the effect of being randomized to a specific treatment regimen, rather than the 
effect of the actual treatment received.
Patients were followed from randomization until viral rebound or censoring at time of death, 
loss to follow-up, or 1012 days. A patient is considered lost to follow-up if his last visit was 
before day 1012 and he had not yet experienced viral rebound or death.. Following Gulick 6, 
a patient’s viral load was “suppressed” if it was below 200 copies/mL, and a patient was 
considered to have experienced viral rebound if his viral load rose above 200 copies/mL 
after dropping below this threshold. Alternative thresholds for suppression and rebound 
could be chosen. We assume that viral load was unsuppressed until the first viral load 
measurement in which viral load was suppressed (and likewise for viral rebound).
To summarize treatment effects, we compare the mean time patients spend in a state of viral 
suppression in each trial arm 9. We define a patient to be in a “state of viral suppression” 
after initial viral suppression and prior to first viral rebound. To estimate this outcome 
measure for one treatment arm, we begin by estimating the probability of being in a state of 
suppression at each time point. Specifically, being suppressed at time t requires that a patient 
has already experienced viral suppression by time t, but not yet experienced viral rebound. 
Accordingly, the probability of being in a state of suppression can be denoted by G(t) and 
estimated for each treatment arm x as , where  is the product limit 
estimator of the Kaplan-Meier survivor function for rebound for treatment arm X = x and 
 is the survivor function for initial viral suppression for that treatment arm. Note that 
 will always be greater than  because, by definition, a patient’s viral load cannot 
rebound before it is suppressed below the threshold value. The quantity Ĝx(t) has the 
intuitive interpretation as the proportion of patients in treatment arm x who have not yet 
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rebounded, excluding those who have not yet initially suppressed. This measure can be 
summarized as the τ -restricted mean time spent in a state of suppression (prior to rebound) 
by integrating Ĝx(t) over the study period τ. Because the survivor functions can change at 
most once per day, the mean time suppressed over the 1012-day follow-up period for 
treatment arm x can be calculated as the Riemann sum . The components 
of this measure for each arm can be seen in figure 1.
The difference in mean time spent in a state of suppression can compared between treatment 
regimens, with inference based on the closed-form equation for the variance presented in 
Supplemental Digital Content: Appendix 1 or a nonparametric bootstrap. Additional 
technical details and SAS computer code are provided in Appendices 1 and 2.
Results
The 761 participants were 81% male, had a mean age of 37, and were predominantly white 
(41%) or black (35%). The prevalence of hepatitis C virus was 10% and the prevalence of 
hepatitis B virus was 3%. Demographic characteristics were similar between the 380 
patients in the 3-drug arm and the 381 patients in the 4-drug arm.
Over the 1012 days of follow-up, 12 patients died (8 in the 3-drug arm and 4 in the 4-drug 
arm) and 236 patients became lost to follow-up (111 in the 3-drug arm and 125 in the 4-drug 
arm). Over the course of follow-up, 356 patients in the 3-drug arm (93.7%) and 354 patients 
in the 4-drug arm (92.9%) responded to treatment by suppressing their HIV-1 RNA viral 
load below 200 copies/mL at one or more time points. The median time from randomization 
to initial viral load suppression was 56 days in both groups. During the course of follow-up, 
121 patients in the 3-drug arm and 112 patients in the 4-drug arm experienced viral rebound 
after initial viral suppression. The probability of being in a state of suppression prior to 
rebound at each time during follow-up, Gx(t), can be seen for both arms in Figure 2. Over 
the 1012-day follow-up period, the average number of days suppressed prior to rebound was 
644 in the 3-drug arm and 686 in the 4-drug arm, for a difference of 42 days in favor of the 
4-drug regimen (95% CI: −11, 96).
Discussion
Using the proposed endpoint, we have demonstrated that the 4-drug regimen conferred a 
slight benefit over the 3-drug regimen in terms of number of days spent in a state of viral 
suppression without viral rebound. These results agree with an existing study using virologic 
failure as the endpoint 6, which noted that the time to virologic failure, defined as the first of 
two successive viral load measurements above 200 copies/mL after 16 weeks, was not 
significantly longer in the 4-drug arm. However, the particular advantages of the 4-drug 
regimen regarding time to initial suppression and rebound are seen more readily using the 
proposed approach.
In addition to providing an endpoint that is readily interpretable and simple to communicate, 
the proposed approach avoids several pitfalls associated with using virologic failure as an 
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endpoint. For example, virologic failure is sometimes defined as the time to the first viral 
load measurement over 200 copies/mL at or after 16 weeks from randomization 5,6. Under 
this definition, the time to virologic failure is set to the ad hoc time point of 16 weeks if the 
patient fails to respond to treatment by achieving a suppressed viral load by that time. When 
the event of interest is virologic failure, the event pool is a mixture of 2 distinct types of 
events: patients who have experienced virologic suppression and then rebound, and patients 
who did not achieve virologic suppression on or before the cut point. Such a composite 
endpoint fails to keep inferences distinct between these event types. For example, use of 
virologic failure as a composite endpoint hides differences in early suppression dynamics 
between treatment arms. Similarly, differences in the time to suppression are hidden if the 
time to virologic failure is estimated as the time from suppression to rebound only among 
patients who suppress.
The approach to measuring viral suppression illustrated here is based on the probability of 
being suppressed over time using ideas from multistate models developed for multiple time-
to-event endpoints10. As formalized by Gouskova et al. 9, this approach can be extended to 
incorporate a time-varying weight to place greater importance on the probability of 
suppression at any time window during follow-up. For example, the weights can be used to 
improve precision by down weighting time points when the probability difference is highly 
variable (e.g., by applying a weight of 1/standard-error of the probability difference at each 
time point). Alternatively, weights can be used to tailor the analysis to research questions 
emphasizing outcomes at certain time windows. For example, if replication ceases at 
treatment initiation for both treatment arms, and the time to suppression is merely a function 
of the size and composition of a patient’s viral reservoir 11–13, early differences in time 
spent in a state of suppression may be clinically less important than differences at later 
times. In this scenario, the investigator could down-weight the differences in the probability 
of suppression at these early time points to focus the analysis on differences in the 
probability of suppression after some clinically relevant time-point. When weights are set to 
1 for all time points, as in the example presented here, the integral of the difference in the 
probability of suppression over time has the intuitive interpretation of the difference in the 
restricted mean number of days suppressed prior to rebound between treatment arms.
We have used this approach to compare the mean number of days spent in a state of 
suppression between arms of a randomized trial. This approach could also be used to 
compare suppression between exposure groups in observational studies using inverse 
probability weights14,15 or the parametric g-formula 16,17 to account for confounding by 
measured variables. Extensions of this approach to observational studies would allow this 
endpoint to be used when examining the effects of exposures that are unlikely to be 
randomized. In addition, while we define a patient to be in a state of viral suppression after 
initial viral suppression and prior to first viral rebound, this approach can be extended to 
allow for multiple cycles of suppression and rebound.
HIV-1 RNA viral load remains an important outcome measure in HIV randomized trials and 
observational studies. We have illustrated an endpoint that uses information on the time to 
viral suppression and time to subsequent viral rebound to provide a single summary measure 
of the mean time spent in a state of viral suppression before viral rebound in each treatment 
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arm. This endpoint is well defined, has an appealing graphical representation, and facilitates 
straightforward comparisons of treatment effects between studies.
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Illustration of the survival curve for suppression a (solid line), the survival curve for rebound 
(dashed line), and the restricted mean time spent in a state of suppression b for 380 patients 
in the 3-drug arm (panel A) and 381 patients in the 4-drug arm (panel B) of the ACTG 
A5095 trial over 1012 days of follow-up
aThe survival curves for initial viral suppression, , and viral rebound,  were 
estimated using the Kaplan-Meier product limit estimator of the survivor function. Details 
are provided in the Supplemental Digital Content: Appendix
bThe restricted mean number of days spent in a state of suppression (i.e., time after initial 
suppression and prior to viral rebound) over the 1012-day follow-up period for each arm 
was estimated as  where 
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Probability of being in a state of suppression prior to viral rebound, Gx(t), for 380 patients in 
the 3-drug arm and 381 patients in the 4-drug arm of the ACTG A5095 trial over 1012 days 
of follow-up
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